As HIV Has Evolved, Dolutegravin Has Become Less Effective In Sub-Saharan Africa
Dolutegravir, the HIV wonder drug and current first-line treatment, is less effective in sub-Saharan Africa, and the reason is as old as evolution itself - mutation.
